Results 101 to 110 of about 8,073 (209)
Abstract 1447: PDE5 inhibitors increase trastuzumab transport for treatment of HER2-positive metastatic brain tumors [PDF]
, 2010 Objective: Chemotherapeutic drugs and newly developed therapeutic antibodies can be adequately delivered to most solid and systemic tumors. However, drug delivery into primary brain tumors and metastases is impeded by the blood-brain tumor barrier (BTB),
Jinwei Hu +9 more
core +1 more source
Optimization of extraction methods for determination of phosphodiesterase-5 (PDE5) inhibitors in premix coffee [PDF]
, 2013 An efficient analytical technique capable of analyzing three most common phosphodiesterase-5 (PDE5) inhibitors (vardenafil, sildenafil and tadalafil) simultaneously in premix coffee was developed.
Tuan Norhafizah binti Tuan Zakaria
core
ChemistryOpenPhosphodiesterase type 5 (PDE5) is a multidomain protein that plays a crucial role in regulating cellular cyclic guanosine monophosphate (cGMP), a key signaling molecule involved in various physiological processes.
Mohd Shahnawaz Khan +5 more
doaj +1 more source
Relationship between the effects of PDE5 inhibitors and oxidative stress on infertility caused by adenomyosis [PDF]
, 2022 application/pdf子宮腺筋症は不妊・不育症に関与している。本研究では、ICRマウスを生後2日目～5日目にタモキシフェンを内服させ、妊娠15週以降には子宮内膜腺が筋層内に侵入した子宮腺筋症を認めた。子宮腺筋症患者の妊娠維持のため、PDE5阻害剤を内服させ血流改善を試みることで妊娠出産を期待し、本マウスの性成熟期にPDE5阻害剤を投与した。その結果、子宮筋層内の内膜腺の増加を認めた。本結果より、子宮筋層への血流増加による内膜腺の増生が考えられた。今後、本マウスを交配させ妊娠結果を検討していきたい。
Maezawa, Tadashi, 前沢, 忠志
core
Patient Preference and Adherence, 2009 Amr Abdel Raheem1, Philip Kell21St. Peter’s Andrology Department, The Institute of Urology, London, and Cairo University, Egypt; 2St. Peter’s Andrology Department, The Institute of Urology, London, UKAbstract: Erectile dysfunction (ED)
Amr Abdel Raheem, Philip Kell
doaj
Frontiers in ChemistryIntroduction: In clinical practice, phosphodiesterase 5 (PDE5) inhibitors are commonly used to treat erectile dysfunction and pulmonary arterial hypertension.
Lihang Qu +6 more
doaj +1 more source
Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients
Journal of Immunology Research, 2017 Sildenafil, a type 5 phosphodiesterase inhibitor (PDE5-I), is primarily used for treating erectile dysfunction. Sildenafil inhibits the degradation of cyclic guanosine monophosphate (cGMP) by competing with cGMP for binding site of PDE5.
Monika Kniotek, Agnieszka Boguska
doaj +1 more source
Research progress of phosphodiesterase 5 in heart failure [PDF]
Jichu yixue yu linchuangPhosphodiesterase 5 (PDE5), a cyclic guanosine monophosphate (cGMP)-specific hydrolase, is targets cGMP produced by soluble guanosine cyclase (sGC) that is activated by nitric oxide (NO). It catalyzes the hydrolysis of the phosphodiester bond in cGMP and
YANG Yang, ZHANG Yarong, YANG Hongqin, WANG Jing, ZHAO Hongmei
doaj +1 more source
In Silico Identification of Promising PDE5 Inhibitors Against Hepatocellular Carcinoma among recently FDA approved drug: A Docking and ADMET Study [PDF]
Introduction: Hepatocellular Carcinoma (HCC) is a prevalent and deadly form of liver cancer. Phosphodiesterase 5 (PDE5) inhibitors, known for treating erectile dysfunction, have shown potential as anti-cancer agents due to their effects on cellular ...
Anil Kumar, Dharmendra Singh Rajput, Naveen Gupta
core +1 more source